• Chlorpromazine in Liver Nanoparticle Research

  2026-10-09

  Chlorpromazine is best known for dopamine D2 receptor antagonism, but its broader pharmacology creates important interpretive questions for liver nanoparticle studies. This article distinguishes established findings from testable hypotheses and explains how chlorpromazine hydrochloride could be considered without overstating evidence.

• Maraviroc and CCR5: Interpreting Evidence Across Models

  2026-10-09

  Maraviroc (UK-427857) is best understood not only as a CCR5 antagonist for HIV-1 entry inhibition, but also as a mechanistic probe whose meaning depends on the model. This evidence-led analysis connects HIV tropism studies with emerging extracellular-vesicle research while defining the limits of translation.

• MRTFA–KCNMB1 Controls Cancer Cell Stiffness

  2026-10-08

  Gajda et al. identify potassium efflux and the BK-channel auxiliary subunit KCNMB1 as regulators of cancer-cell stiffness downstream of MRTFA. The study links mechanically softer cancer cells with immune-cell evasion and metastatic colonization, while showing that BK-channel activation can increase tumor-cell susceptibility to cytotoxic lymphocytes in experimental models.

• T7 RNA Polymerase in RNA Therapeutics Research

  2026-10-08

  T7 RNA Polymerase is a promoter-specific, DNA-dependent enzyme widely used as an upstream tool for research RNA synthesis. This overview distinguishes its conceptual role in in vitro transcription from the preclinical findings of a 2025 lung cancer study using inhaled mRNA and siRNA lipid nanoparticles. It compares the evidence, clarifies what the study does and does not demonstrate about T7 polymerase, and outlines key translational limitations.

• Kanamycin Sulfate: Evidence, Scope and Limits

  2026-10-07

  A source-grounded overview of Kanamycin Sulfate, its aminoglycoside mechanism, and what a recent Clostridioides difficile study does—and does not—show about antibiotic research, toxin inhibition, microbiota findings, and translational relevance.

• Molidustat and Oxygen-Sensing Translation

  2026-10-07

  Molidustat (BAY85-3934) offers a translational lens on how oxygen sensing can be redirected toward endogenous erythropoietin stimulation in chronic kidney disease anemia. This thought-leadership article connects its HIF prolyl hydroxylase mechanism with evidence that Septin4 can intensify VHL-mediated HIF-1α degradation in cardiomyocytes. The result is not a claim that Molidustat treats cardiac injury, but a framework for asking how tissue context, HIF isoform biology, and downstream target selection should shape renal anemia therapy research.

• Prochlorperazine: Clinical and Research Evidence

  2026-10-06

  Prochlorperazine is an established dopamine D2 receptor antagonist used in antiemetic therapy, but its proposed roles in acute mountain sickness, melanoma research, and antiviral research differ substantially in evidence strength. The strongest supplied clinical source is a randomized-trial protocol rather than a completed outcome report, while oncology and antiviral claims remain preliminary and commercially sourced.

• Cyclosporin A as a Translational Mechanistic Probe

  2026-10-06

  Cyclosporin A is best understood not as a universal pathway switch, but as a pharmacological stress test for cyclophilin biology, calcineurin-NFAT signaling, mitochondrial injury, and cell-death programs. This thought-leadership perspective connects mechanistic validation with formulation awareness and translational decision-making.

• Boc-D-FMK: Reading Apoptosis Beyond Cell Death

  2026-10-05

  Boc-D-FMK is a cell-permeable pan-caspase inhibitor used to investigate how caspase activity connects apoptosis with inflammatory signaling. This article presents an evidence-centered framework for interpreting results across endothelial, hepatic, and fibrosis-related models without confusing pathway modulation with proof of mechanism.

• Clozapine as a Mechanistic Comparator in Schizophrenia

  2026-10-04

  Clozapine is an atypical antipsychotic medication with broad receptor activity and distinctive prefrontal ERK1/2 biology. This article uses it as a mechanistic comparator for a 2025 Molecular Psychiatry study on GABRE, clarifying what the evidence shows—and what it does not.

• UBR1 and UBR2: Mammalian ER Stress Sensors

  2026-10-03

  The reference study identifies the N-recognin E3 ligases UBR1 and UBR2 as stress-responsive regulators of mammalian endoplasmic reticulum protein quality control. Its findings connect N-degron-mediated ubiquitination with ER stress adaptation, while also showing why trafficking perturbations and apoptosis phenotypes should not be interpreted as evidence for the same molecular pathway.

• Selective Hypothermic Albumin Perfusion in Stroke

  2026-10-02

  The reference study shows that intra-arterial selective cooling combined with human serum albumin provides stronger protection against cerebral ischemia-reperfusion injury than cooling or albumin delivery alone in a rat middle cerebral artery occlusion model. Its findings connect improved neurological recovery and reduced neuroinflammation with blood-brain barrier preservation involving the ROCK1/MLC pathway and F-actin regulation.

• Patient-Derived Gastric Cancer Assembloids Explained

  2026-10-01

  Shapira-Netanelov et al. developed a patient-derived gastric cancer assembloid model that combines matched tumor organoids with stromal cell subpopulations from the same tumor. The study shows that stromal composition changes gene expression and drug sensitivity, supporting more physiologically relevant tumor modeling and personalized preclinical screening.

• SB-505124 hydrochloride in Fibrosis & Mechanobiology

  2026-10-01

  SB-505124 hydrochloride is a reversible ALK4/5/7 probe for separating TGF-β-driven signaling from downstream fibroblast activation and mechanical phenotypes. This workflow connects phospho-Smad validation, fibrosis assays, glaucoma models, and carefully bounded mechanobiology extensions without treating an exploratory cancer application as established evidence.

• Chenodeoxycholic Acid: From FXR Ligand to Assay Strategy

  2026-09-30

  Chenodeoxycholic Acid (CDCA) is more than a bile acid ligand: it can serve as a mechanistic probe for FXR–KLF11 control of renal inflammatory signaling. This guide translates recent evidence into assay design, formulation, and interpretation decisions for cholesterol metabolism research and kidney injury models.

8124 records 1/542 page Next 12345 下5页 Last page